Rush Ranked in Seven Specialties by U.S. News

RushTowerCloudsRush University Medical Center once again has been named one of the nation’s top hospitals, according to the new issue of U.S. News & World Report. Rush is ranked in seven of 16 categories included in the magazine’s 2014 -15 “America’s Best Hospitals” issue, which became available online on July 15, and is one of the two top-ranked hospitals in Illinois overall.

Rush’s orthopedics program was ranked No. 6 nationwide, making it the highest ranked orthopedics program in Illinois. Rush’s other ranked programs were geriatrics (No. 17); neurology and neurosurgery (No. 17); nephrology (No. 31); urology (No. 43); cardiology and heart surgery (No. 46); and cancer (No. 48).

U.S. News also noted that the following Rush specialty services are “high-performing”: diabetes and endocrinology; ear, nose and throat; gastroenterology; gynecology; and pulmonary.

Continue reading

Cinnamon May Help Halt Parkinson’s Progression

cinnamonNeurological scientists at Rush University Medical Center have found that using cinnamon can reverse the biomechanical, cellular and anatomical changes that occur in the brains of mice with Parkinson’s disease.  Results of the study were published in the June 20 issue of the Journal of Neuroimmune Pharmacology.

“Cinnamon has been used widely as a spice throughout the world for centuries,” said Kalipada Pahan, PhD, study lead researcher and the Floyd A. Davis professor of neurology at Rush.  “This could potentially be one of the safest approaches to halt disease progression in Parkinson’s patients.”

“Cinnamon is metabolized in the liver to sodium benzoate, which is an FDA-approved drug used in the treatment for hepatic metabolic defects associated with hyperammonemia,” said Pahan.  It is also widely used as a food preservative due to its microbiocidal effect.

Chinese cinnamon (Cinnamonum cassia) and original Ceylon cinnamon (Cinnamonum verum) are two major types of cinnamon that are available in the U.S.

Continue reading

Sudden Decline in Testosterone May Cause Parkinson’s Disease Symptoms in Men

The results of a new study by neurological researchers at Rush University Medical Center show that a sudden decrease of testosterone, the male sex hormone, may cause Parkinson’s like symptoms in male mice.  The findings were recently published in the Journal of Biological Chemistry.

One of the major roadblocks for discovering drugs against Parkinson’s disease is the unavailability of a reliable animal model for this disease.

“While scientists use different toxins and a number of complex genetic approaches to model Parkinson’s disease in mice, we have found that the sudden drop in the levels of testosterone following castration is sufficient to cause persistent Parkinson’s like pathology and symptoms in male mice,” said Dr. Kalipada Pahan, lead author of the study and the Floyd A. Davis endowed professor of neurology at Rush. “We found that the supplementation of testosterone in the form of 5-alpha dihydrotestosterone (DHT) pellets reverses Parkinson’s pathology in male mice.”“In men, testosterone levels are intimately coupled to many disease processes,” said Pahan.  Typically, in healthy males, testosterone level is the maximum in the mid-30s, which then drop about one percent each year. However, testosterone levels may dip drastically due to stress or sudden turn of other life events, which may make somebody more vulnerable to Parkinson’s disease.

“Therefore, preservation of testosterone in males may be an important step to become resistant to Parkinson’s disease,” said Pahan.

Read the entire news release.

Neurologists at Rush Working to Discover New Biomarkers for Parkinson’s Disease

Jennifer_GoldmanRush University Medical Center has been named one of only five clinical sites in the U.S. to lead a landmark, two-year, multi-site study exclusively focused on discovering new biomarkers for Parkinson’s disease.     

“The discovery of a biomarker is critical to the development of new and improved treatments for Parkinson’s disease, particularly treatments that could slow or stop the progression of the disease, which is something currently not available,” said Dr. Jennifer G. Goldman, neurologist in the Parkinson’s Disease and Movement Disorders Center at Rush.  Goldman is also an associate professor in the Department of Neurological Sciences at Rush.

This study, called BioFIND, aims to identify new biomarker candidates, which are substances or characteristics found in people’s bodies that are associated with the presence of disease or changes over time in a way that can be linked back to the progression of disease.

The BioFIND study will complement the Parkinson’s Progression Markers Initiative (PPMI), another observational clinical study to comprehensively evaluate a cohort of recently diagnosed PD patients and healthy subjects using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

“The data we collect from the BioFIND study along with the data from PPMI will produce the most comprehensive and long-ranging dataset available for biomarker discovery work throughout the Parkinson’s disease community,” said Goldman.

Read the entire news release.

Number of People with Alzheimer’s Disease May Triple by 2050

senior handsThe number of people with Alzheimer’s disease is expected to triple in the next 40 years, according to a new study by researchers from the Rush Institute of Healthy Aging at Rush University Medical Center.

The findings of the study are  published in the February 6, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

This increase is due to an aging baby boom generation.  It will place a huge burden on society, disabling more people who develop the disease, challenging their caregivers, and straining medical and social safety nets,” said co-author, Jennifer Weuve, MPH, ScD, assistant professor of medicine, Rush Institute for Healthy Aging at Rush University Medical Center in Chicago.

For the study, researchers analyzed information from 10,802 African-American and Caucasian people living in Chicago, ages 65 and older between 1993 and 2011. Participants were interviewed and assessed for dementia every three years. Age, race and level of education were factored into the research.

The data was combined with U.S. death rates, education and current and future population estimates from the U.S. Census Bureau.

The study found that the total number of people with Alzheimer’s dementia in 2050 is projected to be 13.8 million, up from 4.7 million in 2010. About 7 million of those with the disease would be age 85 or older in 2050.

“Our projections use sophisticated methods and the most up-to-date data, but they echo projections made years and decades ago.  All of these projections anticipate a future with a dramatic increase in the number of people with Alzheimer’s and should compel us to prepare for it,” said Weuve.

Read the entire news release.